The expanding therapeutic perspective of CCR5 blockade

Luca Vangelista, Sandro Vento

Research output: Contribution to journalShort surveypeer-review

73 Citations (Scopus)


CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. However, over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies. Expressed on various cell types, CCR5 plays a vital role in the inflammatory response by directing cells to sites of inflammation. Aside HIV-1, CCR5 has been implicated in other infectious diseases and non-infectious diseases such as cancer, atherosclerosis, and inflammatory bowel disease. Individuals carrying the CCR5Δ32 mutation live a normal life and are warranted a natural barrier to HIV-1 infection. Therefore, CCR5 antagonism and gene-edited knockout of the receptor gained growing interest for the therapeutic role that CCR5 blockade may play in the attenuation of the severity or progression of numerous diseases.

Original languageEnglish
Article number1981
JournalFrontiers in Immunology
Issue numberJAN
Publication statusPublished - Jan 12 2018


  • Cancer
  • CCL5
  • CCR5
  • HIV-1
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'The expanding therapeutic perspective of CCR5 blockade'. Together they form a unique fingerprint.

Cite this